Saad F - Search Results

1

Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.

Cadieux B, Coleman R, Jafarinasabian P, Lipton A, Orlowski RZ, Saad F, Scagliotti GV, Shimizu K, Stopeck A. Cadieux B, et al. Among authors: saad f. J Bone Oncol. 2022 Feb 7;33:100416. doi: 10.1016/j.jbo.2022.100416. eCollection 2022 Apr. J Bone Oncol. 2022. PMID: 35242510 Free PMC article. Review.

2

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.

Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J. Lipton A, et al. Among authors: saad f. Cancer Invest. 2002;20 Suppl 2:45-54. doi: 10.1081/cnv-120014886. Cancer Invest. 2002. PMID: 12442349 Review.

3

Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.

Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F. Smith MR, et al. Among authors: saad f. Urology. 2007 Aug;70(2):315-9. doi: 10.1016/j.urology.2007.03.071. Urology. 2007. PMID: 17826496 Free PMC article. Clinical Trial.

4

Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease.

Saad F, Lipton A. Saad F, et al. Semin Oncol. 2007 Dec;34(6 Suppl 4):S17-23. doi: 10.1053/j.seminoncol.2007.10.006. Semin Oncol. 2007. PMID: 18068486 Review.

5

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.

Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE. Lipton A, et al. Among authors: saad f. Cancer. 2008 Jul 1;113(1):193-201. doi: 10.1002/cncr.23529. Cancer. 2008. PMID: 18459173 Free article.

6

Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.

Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body JJ, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL, Weilbaecher KN. Coleman RE, et al. Among authors: saad f. Clin Cancer Res. 2008 Oct 15;14(20):6387-95. doi: 10.1158/1078-0432.CCR-08-1572. Clin Cancer Res. 2008. PMID: 18927277 Free PMC article. Review.

7

SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.

Saad F, Lipton A. Saad F, et al. Cancer Treat Rev. 2010 Apr;36(2):177-84. doi: 10.1016/j.ctrv.2009.11.005. Epub 2009 Dec 16. Cancer Treat Rev. 2010. PMID: 20015594 Review.

8

Bone-marker levels in patients with prostate cancer: potential correlations with outcomes.

Saad F, Lipton A. Saad F, et al. Curr Opin Support Palliat Care. 2010 Sep;4(3):127-34. doi: 10.1097/SPC.0b013e32833ac6d6. Curr Opin Support Palliat Care. 2010. PMID: 20489645 Review.

9

Consensus on the utility of bone markers in the malignant bone disease setting.

Coleman R, Costa L, Saad F, Cook R, Hadji P, Terpos E, Garnero P, Brown J, Body JJ, Smith M, Lee KA, Major P, Dimopoulos M, Lipton A. Coleman R, et al. Among authors: saad f. Crit Rev Oncol Hematol. 2011 Dec;80(3):411-32. doi: 10.1016/j.critrevonc.2011.02.005. Epub 2011 Mar 15. Crit Rev Oncol Hematol. 2011. PMID: 21411334 Review.

10

Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration.

Berruti A, Cook R, Saad F, Buttigliero C, Lipton A, Tampellini M, Lee KA, Coleman RE, Smith MR. Berruti A, et al. Among authors: saad f. Oncologist. 2012;17(5):645-52. doi: 10.1634/theoncologist.2011-0448. Epub 2012 Apr 20. Oncologist. 2012. PMID: 22523198 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,343 results

Search Page